We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Xcellerex Initiates Phase I Clinical Trial of Yellow Fever Vaccine

Xcellerex Initiates Phase I Clinical Trial of Yellow Fever Vaccine

Xcellerex Initiates Phase I Clinical Trial of Yellow Fever Vaccine

Xcellerex Initiates Phase I Clinical Trial of Yellow Fever Vaccine

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xcellerex Initiates Phase I Clinical Trial of Yellow Fever Vaccine"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xcellerex, Inc. has announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal. The company is developing the vaccine to prevent yellow fever in persons traveling to tropical countries where yellow fever is endemic. The only currently available yellow fever vaccine is an attenuated, live vaccine with rare but potentially serious adverse effects.

XRX-001 is an inactivated virus vaccine adsorbed to alum adjuvant. Because it is inactivated and non-replicating, it is anticipated to significantly reduce the risks of serious and fatal adverse events that are sometimes associated with the live yellow fever vaccine.

In addition, the absence of foreign proteins derived from hens’ eggs should also reduce the risk of allergic reactions and eliminate the need to exclude egg-allergic people from vaccination. In addition, Xcellerex believes that the XRX-001 vaccine should not be subject to the precautions and contraindications of the currently marketed live vaccine. These precautions and contraindications, which are all related to potential serious outcomes of replicating live virus infection, include age <9 months or >65 years, immune suppression due to thymectomy, HIV/AIDS, cancer, treatment with immunosuppressive medications or radiation, and pregnancy.

“The initiation of the Phase I clinical trial is a significant milestone for Xcellerex and is further validation of both our disposable manufacturing technology and business model.”

The double-blind, controlled Phase I trial will enroll 60 healthy subjects divided into three groups. Two groups of volunteers will receive two different dose levels of XRX-001 and the third will receive placebo. The primary objective of the trial is to evaluate the safety and tolerability of XRX-001 vaccine, and secondary objectives will assess the neutralizing antibody response - an accepted correlate of protective immunity to yellow fever.

In a second parallel trial, the Company will compare the antibody response in those receiving XRX-001 to travelers receiving the currently-marketed vaccine.